1-[2-(Trifluoromethyl)benzenesulfonyl]piperazine hydrochloride

Catalog No.: 
ACLFST845
CAS No.: 
1803586-83-5
Molecular Formula: 
C11H14ClF3N2O2S
Molecular Weight: 
330.76
1-[2-(Trifluoromethyl)benzenesulfonyl]piperazine hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$163.00InquiryInquiry
250mg95%$226.00InquiryInquiry
1g95%$439.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-[2-(Trifluoromethyl)benzenesulfonyl]piperazine hydrochloride
IUPAC Name1-((2-(trifluoromethyl)phenyl)sulfonyl)piperazine hydrochloride
MDL No.MFCD28145645
Molecular FormulaC11H14ClF3N2O2S
Molecular Weight330.76
SMILESO=S(N1CCNCC1)(C2=CC=CC=C2C(F)(F)F)=O.[H]Cl
InChI KeyUYTXHFIOMKVAEK-UHFFFAOYSA-N
Synonym1-[2-(trifluoromethyl)benzenesulfonyl]piperazine hydrochloride
CAS No.1803586-83-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACLFST845 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. ACLAGT540 route compound structure diagram
    ACLAGT540776-04-5In Stock
  4. Then
  5. ACLFST845 route product structure diagram
    ACLFST8451803586-83-5
Inquiry

2. ACLFST845 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLFST845 route product structure diagram
    ACLFST8451803586-83-5
Inquiry

3. ACLFST845 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLFST845 route product structure diagram
    ACLFST8451803586-83-5
Inquiry

Comments (0)